VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Key Financial Performance
Revenue for the third quarter $0.6 million, a 32% increase year-over-year. The increase is attributed to the early stage of commercialization, though revenues remain unpredictable.
Operating expenses for the quarter Down 10% year-over-year and down 18% for the first three quarters. The decrease is primarily due to lower personnel costs and reduced research and development expenses.
Net cash used in operating activities $3.6 million for the quarter, a 33% reduction year-over-year. This improvement is due to strong cost management.
Net loss for the quarter Down 8% year-over-year and down 20% for the first three quarters. The reduction is attributed to cost management and lower operating expenses.
Receipts during the third quarter $1.2 million from a registered direct offering, including participation by some directors.
Subsequent to quarter end Net proceeds of approximately $6.1 million from a confidentially marketed public offering, including partial exercise of the underwriters' overallotment option.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nu.Q platform commercialization: Signed agreements with Werfen and Hologic for APS and co-marketing Nu.Q Discover service respectively. Werfen will validate Nu.Q NETs assay for APS management, a market worth $85 million annually. Hologic will expand Nu.Q Discover services for epigenetic profiling.
Capture-Seq technology: Developed a new liquid biopsy method targeting cancer-derived DNA, achieving 100% sensitivity and specificity in initial tests. This method isolates transcription factor-bound DNA, representing a new class of cancer biomarkers.
Nu.Q Vet cancer test: Progress in automating centralized lab platforms with Fujifilm Vet Systems to expand canine cancer screening. Targeting inclusion in annual pet wellness panels for 2026.
APS market: APS diagnosis and monitoring represent a $85 million annual market. Nu.Q NETs test could improve diagnostics and monitoring.
Cancer and sepsis diagnostics: Combined total addressable market of $25 billion annually, with potential for significant revenue growth through licensing agreements.
Revenue growth: Revenue grew 32% year-over-year to $0.6 million in Q3 2025.
Cost management: Operating expenses decreased by 10% year-over-year, and cash used in operations reduced by 33%.
Licensing agreements: Focused on securing licensing agreements in human diagnostics, mirroring veterinary market strategy.
Global expansion: Expanding Nu.Q Vet cancer test globally through partnerships with Antech, Fujifilm Vet Systems, and IDEXX.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Revenue for the third quarter grew 32% over the same quarter last year, but revenues remain fairly lumpy and difficult to predict from one quarter to the next. This unpredictability poses a challenge for financial planning and stability.
Strategic Execution Risks: The company is heavily reliant on executing several significant licensing agreements in the human diagnostics space and securing milestone payments in the veterinary space to achieve cash neutrality. Failure to close these deals could impact financial sustainability.
Regulatory Hurdles: The company is working on validating and verifying its tests in various markets, which may face regulatory challenges and delays, particularly in the human diagnostics space.
Economic Uncertainties: The company has made progress in cost reductions, but achieving cash neutrality is contingent on external factors like licensing agreements and milestone payments, which are subject to market and economic conditions.
Supply Chain and Operational Risks: The company is focused on centralized lab automation to handle larger test volumes. Any delays or issues in automation implementation could hinder growth and operational efficiency.
Competitive Pressures: The company is in discussions with around 10 leading diagnostic and liquid biopsy companies. The competitive landscape could impact the company's ability to secure favorable licensing agreements and market share.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company will not be providing revenue guidance at this point in time due to the early stage of commercialization and the unpredictable nature of revenues.
Licensing Agreements: The company is focused on executing several significant licensing agreements in the human diagnostics space and securing milestone payments in the veterinary space to achieve cash neutrality.
Nu.Q Vet Cancer Test: The company aims to expand the global reach of the Nu.Q Vet cancer test, focusing on centralized lab automation to accelerate revenue growth. The goal is to include the test in annual pet wellness panels by 2026, which would significantly increase sales volumes.
Nu.Q NETs Commercialization: The company plans to leverage its CE Mark approval in the EU for NETosis-related diseases and anticipates presenting and publishing results regarding the clinical utility of the Nu.Q NETs H3.1 assay across a range of diseases in the coming months and quarters.
Capture-Seq Technology: The company has developed a new liquid biopsy method, Capture-Seq, which isolates cancer-derived DNA with high specificity and sensitivity. This technology is expected to be a game changer in the liquid biopsy field and is currently in active discussions with third parties for potential licensing.
Nu.Q Discover Service: The company has partnered with Hologic to co-market the Nu.Q Discover service, which provides assays for epigenetic profiling. This partnership is expected to accelerate the expansion of Nu.Q services to a wider customer base and drive revenue growth.
Cancer and Sepsis Diagnostics: The company is targeting the cancer and sepsis diagnostics market, which represents a combined total addressable market of approximately $25 billion annually.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide some additional color on the size of the antiphospholipid syndrome market and how it compares to other potential Nu.Q NET applications?
A:The NET market is huge, with major applications like sepsis and AKI. Antiphospholipid syndrome (APS) affects 4 million people globally, with a total addressable market (TAM) of $85-$90 million annually. APS is a good starting point for Nu.Q NET applications, and the company expects to expand to other uses, with Revvity analyzing 21 additional applications.
Q:Could you tell us whether the Werfen partnership has made any contribution to the third quarter revenue? How do you expect the Werfen and Hologic partnerships to shape the top-line revenue trend in 2026?
A:Werfen has not contributed to Q3 revenue as they are validating clinical samples. Hologic has made its first sale, which will contribute to Q4 revenue. Both partnerships are expected to significantly impact growth, with Werfen broadening its relationship and Hologic actively marketing and training its workforce. The partnerships are transformative and expected to drive adoption of the NETosis test and oncology applications globally.
Q:With respect to ongoing discussions with additional partnerships, how many do you expect to close in 2026?
A:The company cannot predict the exact timing of partnership closures due to the complexity of negotiations. However, they expect to close several deals in 2026, as their NETosis test and oncology platform gain traction and credibility.
Q:Can you give some sort of breakdown of the product revenues? Was there any stocking for Fuji or lumpiness in the Discover side?
A:Product revenues remain lumpy and project-based. All revenue pillars showed progress, and growth is expected across all pillars for the full year. The Nu.Q Vet test is the biggest-selling oncology test in the veterinary market, and Fuji has validated the i10 platform, which is expected to drive adoption in wellness panels.
Q:Do you think there will be a time where you'll actually break down revenue by product line or subsegment revenue line?
A:As revenue lines mature and become more meaningful, the company may provide detailed breakdowns. Currently, revenues are relatively small and lumpy, so they are not split further. The company expects licensing revenue to eventually surpass product revenue as adoption grows.
Q:Do you think you've come to the end of the cost-cutting program, or is there still more to come?
A:The company has made significant progress in cost-cutting but acknowledges that further reductions may be challenging. They aim to balance cost control with delivering deals and products, ensuring expenses remain tight while focusing on growth.
Q:Was there any new information presented from the ongoing lung cancer study?
A:No new information was presented recently. However, significant data is expected to be shared at a conference in Chicago in December, and the test is anticipated to be in routine use soon.
Q:Were there any upfront payments in the agreements with Werfen and Hologic?
A:Yes, Werfen included upfront and ongoing payments, though details are confidential. Hologic's agreement is co-marketing based, with no upfront payments, but they have made their first sales.
Q:When might the milestone for the feline cancer testing hit?
A:The milestone is tied to publishing a paper, which is in progress. Once published, the payment will follow based on the agreement terms.
Q:Have the Series A warrants milestone conditions been met?
A:No, the milestone conditions for the Series A warrants, which require aggregate milestone payments, have not yet been met.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the exact timing of partnership closures in 2026, citing the complexity of negotiations. They also did not provide specific details on the breakdown of product revenues or the exact timeline for the feline cancer testing milestone.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APS patient
Capture Seq
DNA blood
DNA method
DNA sequence
Dr Micallef
Micallef Chief
NET
Nu TriMethyl
Nu service
TriMethyl test
agreement Hologic
background DNA
base
biomarkers hundred
biopsy method
blood sample
cancer DNA
cancer biomarkers
cancer patient
cancer product
class cancer
co marketing
complication
detection
factor CTCF
factor DNA
factor cancer
leader
license
option
plasma
reach
target
thrombosis
transcription factor
VNRX Transcript
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call summary shows positive financial metrics such as a 25% revenue increase and improved net loss, gross margin, and cash flow. However, the absence of strategic initiatives, operational updates, and return discussions, coupled with the acknowledgment of risks in forward-looking statements, balances the sentiment. Without additional insights from the Q&A section, the sentiment remains neutral, lacking strong catalysts for significant stock price movement.
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
Positive4-1
The earnings call reveals a strong financial performance with significant revenue growth and reduced expenses, indicating improved operational efficiency. Despite uncertainties in licensing agreements and future funding, the company has secured substantial nondilutive funding, mitigating immediate financial concerns. The Q&A indicates potential for growth through partnerships and global expansion, though management's lack of specific guidance introduces some uncertainty. Overall, the company's strategic developments and financial improvements suggest a positive outlook for the stock price in the short term.
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Positive8-15
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
VNRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
